| Asthma

Dulera vs Nucala

Side-by-side clinical, coverage, and cost comparison for asthma.

Deep comparison between: Dulera vs Nucala with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsNucala has a higher rate of injection site reactions vs Dulera based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Nucala but not Dulera, including UnitedHealthcare

Category

Dulera

Nucala

At A Glance

RouteOral inhalation

FrequencyTwice daily

ClassICS/LABA combination

RouteSC injection

FrequencyEvery 4 weeks

ClassIL-5 antagonist

Indications

Asthma

Asthma
Chronic rhinosinusitis with multiple nasal polyps
Chronic Obstructive Airway Disease
Eosinophilic granulomatosis with polyangiitis
Hypereosinophilic syndrome

Dosing

Asthma (>=12 years) 2 inhalations twice daily of DULERA 100 mcg/5 mcg or 200 mcg/5 mcg via oral inhalation; maximum 2 inhalations of 200 mcg/5 mcg twice daily (800 mcg/20 mcg per day).

Asthma (5 to <12 years) 2 inhalations of DULERA 50 mcg/5 mcg twice daily via oral inhalation; maximum daily dose 200 mcg/20 mcg.

Asthma (>=12 years), Chronic rhinosinusitis with multiple nasal polyps, Chronic Obstructive Airway Disease 100 mg SC once every 4 weeks.

Asthma (6-11 years) 40 mg SC once every 4 weeks.

Eosinophilic granulomatosis with polyangiitis, Hypereosinophilic syndrome 300 mg SC once every 4 weeks, administered as 3 separate 100 mg injections at least 5 cm apart.

Contraindications

Primary treatment of status asthmaticus or acute episodes of asthma requiring intensive measures
Known hypersensitivity to mometasone furoate, formoterol fumarate, or any ingredient in DULERA

History of hypersensitivity to mepolizumab or excipients in the formulation

Drug Interactions

1518View drug interactions

378View drug interactions

Adverse Reactions

Most common (>=3%) Nasopharyngitis, sinusitis, headache; dysphonia reported at 4-5% in long-term (52-week) treatment; influenza, upper respiratory tract infection in pediatric patients aged 5 to <12 years.

Serious Serious asthma-related events (hospitalizations, intubations, death), cardiovascular and CNS effects, Candida albicans infection, immunosuppression, hypercorticism and adrenal suppression, growth effects in pediatrics, glaucoma and cataracts.

Postmarketing Angina pectoris, cardiac arrhythmias (atrial fibrillation, ventricular extrasystoles, tachyarrhythmia), vision blurred, anaphylactic reaction, angioedema, severe hypotension, rash, pruritus, QT prolongation, blood pressure increased, hypokalemia, hyperglycemia, asthma aggravation (cough, dyspnea, wheezing, bronchospasm).

Most common (>=3%) headache, injection site reaction, back pain, fatigue, oropharyngeal pain, arthralgia, diarrhea, urinary tract infection, cough, pruritus, eczema

Serious herpes zoster

Postmarketing hypersensitivity reactions including anaphylaxis

Pharmacology

DULERA combines mometasone furoate, a synthetic corticosteroid with potent anti-inflammatory activity that inhibits multiple cell types and inflammatory mediators involved in the asthmatic response, and formoterol fumarate, a selective long-acting beta2-adrenergic receptor agonist (LABA) that relaxes bronchial smooth muscle by stimulating adenyl cyclase and inhibiting mast cell mediator release.

Mepolizumab is an IL-5 antagonist (IgG1 kappa) that binds IL-5 with high affinity, blocking its binding to the alpha chain of the IL-5 receptor complex on eosinophils, thereby inhibiting IL-5 signaling and reducing eosinophil production and survival.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Dulera